EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.
Issue link: https://digital.eyeworld.org/i/387844
61 EW CORNEA October 2014 lenses, Dr. Colby said. Those that do remain at risk are patients with underlying autoimmune diseases and those with dense retroprosthetic membranes. Episodes of sterile vitritis are not common and generally respond to topical steroids or sub-Tenon's ste- roid injections, but the underlying cause remains a mystery, Dr. Colby said. Diagnosing the condition can also be a challenge for surgeons less experienced with the KPro. "It's kind of a scary thing when new KPro surgeons have their first episode of this," she said. "If someone comes into your office and they've had acute loss of vision and you see the vitreous is full of opacities, sometimes it can be challenging to decide if it's an infectious endophthalmitis or if it's inflammato y vitritis. If a patient presents and the eye is quiet and there's no pain, it's generally the sterile version rather than an infectious endophthalmitis." Looking ahead Developing and improving the KPro has been a "labor of love," said Dr. Colby. "All cornea specialists should be grateful to Claes Dohlman, MD, PhD, who has spent his life working on this device." During the early years of the KPro, complication rates were in- credibly high, but the introduction of antibiotics to reduce infection, holes in the back plate, and the bandage contact lens that reduced future is bright for improvements from here." EW Editors' note: Dr. Colby has no fina - cial interests related to her comments. corneal melting made it a viable option, Dr. Colby said. "It's a wonderful device. It's not without its complications, but we've come a long way, and the Contact information Colby: kathryn_colby@meei.harvard.edu Meibomian Gland Dysfunction is treatable. Eliminate the guesswork of dry eye. Identify, diagnose and treat MGD with confidence. Visit us at Booth 3153, AAO Chicago to learn more about the TearScience ® Solution for MGD, featuring LipiView ® and LipiFlow ® . Give MGD a Second Glance structural change (severe gland atrophy and drop out) normal meibomian gland structure structural change (duct dilation, gland atrophy and drop out) tearscience.com 919-459-4880 sales@tearscience.com "It's a wonderful device. It's not without its complications, but we've come a long way, and the future is bright for improvements from here." –Kathryn Colby, MD, PhD